Home ExThera Medical Corporation

ExThera Medical Corporation

    Seraph® 100 Blood Filter Receives CE Mark

    This CE Mark signifies that Seraph 100 meets the safety and performance requirements for medical devices in the European Economic Area (EEA) as an adjunct to anti-infective therapy, and it gives ExThera access to a market of 500 million people.

    ExThera Medical Announces Creation of European Subsidiary

    3/19/18: Carla Kikken-Jussen Appointed as Managing Director to Oversee the Strategic Direction of ExThera Medical’s Operations in Europe.

    ‘Seraph’ Blood Filter Successfully Completes Pre-Clinical Testing in Final Phase of DARPA’s DLT Program Reported by ExThera Medical Corporation

    1/25/18: ExThera Medical Corporation, developer of innovative therapies for removing bacteria and viruses from blood, announced that the safety and effectiveness of its Seraph® 200 Microbind® Affinity Blood Filter (Seraph 200) has been demonstrated in pre-clinical testing.